ArticleMethods and protocols2021
Recent Advances in miRNA Delivery Systems.
Article in Methods and protocols, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 167 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
167 citing papers in PubMed, 2 syntheses or guidelines pooled it, 290 citations in OpenAlex.
- Integrative role of small non-coding RNAs in viral immune response: a systematic review.Molecular biology reports · 2024Pooled it
- MicroRNAs in Tumor Endothelial Cells: Regulation, Function and Therapeutic Applications.Cells · 2023Pooled it
- MicroRNA-Ferroptosis-Spinal Cord Injury: A Complex Interplay in Neurodegeneration and Repair.International journal of molecular sciences · 2026Review
- MicroRNAs in Spinal Cord Injury: Molecular and Translational Insights.Brain and behavior · 2026Review
- Targeting Spatiotemporal Heterogeneity of oncomiRNAs: A New Frontier in Cancer Therapy.Cancer reports (Hoboken, N.J.) · 2026Review
- The Promise and Pursuit of MicroRNAs for Cancer Treatment.Biomolecules · 2026Review
- miR-23a-3p as a Biomarker Associated with Prediabetes in People Living with HIV: An Integrative Analysis of Inflammatory, Metabolic, and Insulin Resistance Signatures.International journal of molecular sciences · 2026Article
- Mechanisms and precision interventions in sarcopenia and osteoarthritis comorbidity: A narrative review.Journal of orthopaedic translation · 2026Review
- Empowering women's health with miRNA-integrated nanochemical approaches: from reproductive health to cancer care.RSC advances · 2026Review
- miRNA-1231 Regulated EGFR Signaling: A Potential Therapeutic Target for Hepatocellular Carcinoma.Applied biochemistry and biotechnology · 2026Article
- Role of tumor‑infiltrating lymphocytes and miR‑155 in breast cancer: Insights into carcinogenesis and their potential as prognostic biomarkers (Review).Oncology reports · 2026Review
- Expression Analysis of miRNA Profiles in Colorectal Cancer with a Bioinformatics Approach: An Emphasis on miR-4295, miR-4720-5p, miR-4773, and miR-6831-5p.Diagnostics (Basel, Switzerland) · 2026Article
- Riding the Wave of Progress: Examining the Current Landscape and Future Potential of MicroRNAs in Cancer Gene Therapy.Current gene therapy · 2026Review
- Renal-targeted exosomes inhibiting miR-182-5p for treatment of renal ischemia-reperfusion injury.Bioengineering & translational medicine · 2026Article
- The dual facets of MiRNA in modulating NF-κB in breast cancer.Cancer cell international · 2025Review
- Therapeutic potential of miRNA-26a-encapsulated nanoparticles against hepatocellular carcinoma in a murine model.Liver research (Beijing, China) · 2025Article
- Circulating MiRNAs in thyroid cancer: prognostic promise of miR-155 and limitations of miR-429.Molecular biology reports · 2025Article
- Recent advances in gene delivery for melanocyte-associated disorders.Advanced drug delivery reviews · 2025Review
- Extracellular vesicle microRNA cargoes: candidates for diagnosis and targeted therapy of cutaneous wound healing.Annals of medicine · 2025Review
- Roles of noncoding RNAs in neuropathic pain.Pain reports · 2025Review
107 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) represent a family of short non-coding regulatory RNA molecules that are produced in a tissue and time-specific manner to orchestrate gene expression post-transcription. MiRNAs hybridize to target mRNA(s) to induce translation repression or mRNA degradation. Functional studies have demonstrated that miRNAs are engaged in virtually every physiological process and, consequently, miRNA dysregulations have been linked to multiple human pathologies. Thus, miRNA mimics and anti-miRNAs that restore miRNA expression or downregulate aberrantly expressed miRNAs, respectively, are highly sought-after therapeutic strategies for effective manipulation of miRNA levels. In this regard, carrier vehicles that facilitate proficient and safe delivery of miRNA-based therapeutics are fundamental to the clinical success of these pharmaceuticals. Here, we highlight the strengths and weaknesses of current state-of-the-art viral and non-viral miRNA delivery systems and provide perspective on how these tools can be exploited to improve the outcomes of miRNA-based therapeutics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.